CNBC Pro

Credit Suisse initiates coverage of 23andMe at outperform, says stock can rise 78%

Anne Wojcicki, 23andMe co-founder & CEO (right) celebrates with 23andMe employees after remotely ringing the NASDAQ opening bell at the headquarters of DNA tech company 23andMe in Sunnyvale, California, U.S., June 17, 2021.
Peter DaSilva | Reuters

The health care potential of genetics company 23andMe should give investors a massive return, according to Credit Suisse.

More In Street Calls

CNBC ProBank of America upgrades BJ's to buy, says retailer will outperform in an inflationary environment
CNBC ProSell United Rentals ahead of construction slump, Bernstein says
CNBC ProHere are Thursday's biggest analyst calls: Sunrun, Zoom, Mattel, Starbucks, Bed Bath & Beyond & more